POLYMED Poly Medicure Q1 FY26 results (Apr–Jun 2025) and concall
Poly Medicure is aggressively pivoting towards high-technology medical device adjacencies, specifically orthopedics and cardiology, through the acquisitions of Citieffe and PendraCare. The Citieffe acquisition provides a vertically integrated platform in the $12 billion trauma and extremity market with high gross margins and established direct sales channels in the US and Europe. Management is focused on leveraging their global distribution network and R&D capabilities to drive operating leverage and product expansion.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 420 | 424 | 441 | 403 |
| EBITDA | 115 | 114 | 119 | 106 |
| Net profit | 87 | 85 | 92 | 93 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
